
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : rGDF11
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Prime Movers Lab
Deal Size : $40.0 million
Deal Type : Series A Financing
Details : The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for GDF11, for lead indication of stroke recovery.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : rGDF11
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Prime Movers Lab
Deal Size : $40.0 million
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : rGDF11
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Prime Movers Lab
Deal Size : $15.0 million
Deal Type : Financing
Elevian Announces $15 Million Equity Financing
Details : Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : rGDF11
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Prime Movers Lab
Deal Size : $15.0 million
Deal Type : Financing
